CD38 antibodies in multiple myeloma: back to the future
Niels W.C.J. van de Donk(Amsterdam UMC Location Vrije Universiteit Amsterdam), Fabio Malavasi(University of Turin)
Cited by 482
Related Papers
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
|Blood|2016|377
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
|Leukemia|2015|266
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential
|Blood|2007|160